Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Sep 28;12(9):e066624.
doi: 10.1136/bmjopen-2022-066624.

Peer Reviewed Evaluation of Registered End-Points of Randomised Trials (the PRE-REPORT study): a stepped wedge, cluster-randomised trial

Affiliations
Randomized Controlled Trial

Peer Reviewed Evaluation of Registered End-Points of Randomised Trials (the PRE-REPORT study): a stepped wedge, cluster-randomised trial

Christopher W Jones et al. BMJ Open. .

Abstract

Objective: To test whether providing relevant clinical trial registry information to peer reviewers evaluating trial manuscripts decreases discrepancies between registered and published trial outcomes.

Design: Stepped wedge, cluster-randomised trial, with clusters comprised of eligible manuscripts submitted to each participating journal between 1 November 2018 and 31 October 2019.

Setting: Thirteen medical journals.

Participants: Manuscripts were eligible for inclusion if they were submitted to a participating journal during the study period, presented results from the primary analysis of a clinical trial, and were peer reviewed.

Interventions: During the control phase, there were no changes to pre-existing peer review practices. After journals crossed over into the intervention phase, peer reviewers received a data sheet describing whether trials were registered, the initial registration and enrolment dates, and the registered primary outcome(s) when enrolment began.

Main outcome measure: The presence of a clearly defined, prospectively registered primary outcome consistent with the primary outcome in the published trial manuscript, as determined by two independent outcome assessors.

Results: We included 419 manuscripts (243 control and 176 intervention). Participating journals published 43% of control-phase manuscripts and 39% of intervention-phase manuscripts (model-estimated percentage difference between intervention and control trials = -10%, 95% CI -25% to 4%). Among the 173 accepted trials, published primary outcomes were consistent with clearly defined, prospectively registered primary outcomes in 40 of 105 (38%) control-phase trials and 27 of 68 (40%) intervention-phase trials. A linear mixed model did not show evidence of a statistically significant primary outcome effect from the intervention (estimated difference between intervention and control=-6% (90% CI -27% to 15%); one-sided p value=0.68).

Conclusions: These results do not support use of the tested intervention as implemented here to increase agreement between prospectively registered and published trial outcomes. Other approaches are needed to improve the quality of outcome reporting of clinical trials.

Trial registration number: ISRCTN41225307.

Keywords: GENERAL MEDICINE (see Internal Medicine); STATISTICS & RESEARCH METHODS; World Wide Web technology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/disclosure-of-interest/ and declare: no support from any commercial organisation for the submitted work; CJ has received research grants from AstraZeneca, Vapotherm, Abbott, and Ophirex outside the submitted work. SS is a full time employee at BMJ but is not involved in editorial decision-making on manuscripts. BM is an employee of the Department of Health and Human Services in the Office of Research Integrity. DLS is an associate editor at JAMA and a deputy editor at Annals of Emergency Medicine. TFP-M is an employee of Ophirex; no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1
Flow diagram of eligible and included trials.
Figure 2
Figure 2
Proportion of accepted papers with clear, prospectively registered primary outcomes that match the published primary outcomes, by intervention phase and study month. Includes loess smoothing lines.

Similar articles

Cited by

References

    1. Dickersin K, Rennie D. Registering clinical trials. JAMA 2003;290:516–23. 10.1001/jama.290.4.516 - DOI - PubMed
    1. Tonks A. Registering clinical trials. BMJ 1999;319:1565–8. 10.1136/bmj.319.7224.1565 - DOI - PMC - PubMed
    1. DeAngelis CD, Drazen JM, Frizelle FA, et al. . Clinical trial registration: a statement from the International Committee of medical Journal editors. JAMA 2004;292:1363–4. 10.1001/jama.292.11.1363 - DOI - PubMed
    1. Assembly WH, World Health Organization . Ministerial Summit on health research: report by the Secretariat, 2005. Available: https://apps.who.int/iris/handle/10665/20304
    1. Regulation (EU) NO 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing directive 2001/20/ED. European Union, 2014. Available: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32014R0536

Publication types

LinkOut - more resources